NASDAQ:AGIO Agios Pharmaceuticals Q3 2026 Earnings Date & Estimates $31.81 -0.11 (-0.34%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$31.82 +0.01 (+0.03%) As of 10/9/2026 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Agios Pharmaceuticals is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for 8:00 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeBefore Market OpensConference Call8:00 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Agios Pharmaceuticals in Q3 2026Agios Pharmaceuticals is expected to post earnings of -$1.24 per share on revenue of $51.95 million. In the same quarter a year earlier Agios Pharmaceuticals reported -$1.78 per share on revenue of $12.88 million. Agios Pharmaceuticals last reported on July 30, 2026, posting -$1.69 per share and missing the -$1.65 consensus estimate. Agios Pharmaceuticals has beaten the consensus EPS estimate in 4 of its last 8 quarters.Consensus EstimatesConsensus EPS-$1.24Expected Revenue$51.95 millionPrior-Year EPS-$1.78Prior-Year Revenue$12.88 millionExpected Revenue Growth+303.3%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$1.69 (Missed by -$0.04)Last Quarter Revenue$44.75 millionEPS Beat Rate4 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ3 2025 Earnings Report Agios Pharmaceuticals Q3 2026 Earnings FAQ When does Agios Pharmaceuticals report Q3 2026 earnings? Agios Pharmaceuticals (NASDAQ:AGIO) is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. What time is Agios Pharmaceuticals' Q3 2026 earnings call? Agios Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Agios Pharmaceuticals? Analysts expect Agios Pharmaceuticals to post earnings of -$1.24 per share for Q3 2026. How much revenue is Agios Pharmaceuticals expected to report? The consensus revenue estimate for Agios Pharmaceuticals is $51.95 million for Q3 2026. Agios Pharmaceuticals Earnings HeadlinesAgios Pharma (AGIO) Gets a Hold from RBC Capital7 minutes ago | theglobeandmail.comAgios Pharmaceuticals (AGIO) Could Be 28% Undervalued Following Its November Results Call DateOctober 10 at 1:45 AM | finance.yahoo.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.October 10 at 1:00 AM | Porter & Company (Ad)Agios Pharmaceuticals (AGIO) Stock Looks Fully Priced Against Current SalesOctober 10 at 1:45 AM | finance.yahoo.comTruist Financial Has Lowered Expectations for Agios Pharmaceuticals (NASDAQ:AGIO) Stock PriceOctober 9 at 1:43 AM | americanbankingnews.comAgios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ETOctober 8 at 7:00 AM | globenewswire.comSee More Agios Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Agios Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Agios Pharmaceuticals and other key companies, straight to your email. Email Address About Agios PharmaceuticalsAgios Pharmaceuticals (NASDAQ:AGIO) is a biopharmaceutical company focused on discovering and developing medicines for rare diseases. Based in Cambridge, Massachusetts, the company specializes in cellular metabolism and the development of therapies designed to address underlying disease biology rather than only treating symptoms. Agios’ lead commercial product is Pyrukynd (mitapivat), an oral pyruvate kinase activator approved for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder. The company is also evaluating mitapivat in additional hematologic conditions, including sickle cell disease and thalassemia, and is advancing other investigational programs for rare diseases. Agios was founded in 2008 and initially built a pipeline focused on cancer metabolism. It subsequently shifted its strategic emphasis to genetically defined diseases and completed the sale of its oncology portfolio to Servier in 2020, while retaining certain rights and pursuing milestone opportunities connected with those programs. Agios serves patients and healthcare providers primarily in the United States and other markets where its products and programs are approved or under development. Brian Goff has served as the company’s chief executive officer since 2023.View Agios Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
